Thousands of women diagnosed with high-risk, estrogen-receptor-positive breast cancer may no longer need chemotherapy, according to results from the OPTIMA trial set for presentation at the 2026 American Society of Clinical Oncology annual meeting. The trial, led by researchers at University College London and University College London Hospitals and funded by the National Institute for Health and Care Research, used the Prosigna genomic test to sort patients into groups based on their likely benefit from chemotherapy. The central finding: roughly two-thirds of patients classified as high-risk by standard clinical measures showed no meaningful advantage from adding chemotherapy to their endocrine therapy.
Why Prosigna-guided treatment decisions matter right now
For years, oncologists have known that some women with hormone-receptor-positive breast cancer receive chemotherapy they do not need. The drugs carry serious side effects, from neuropathy to cardiac damage, and the treatment burden falls hardest on patients whose tumors would have responded just as well to endocrine therapy alone. The problem has been separating those patients from the ones who genuinely benefit. Standard clinical risk tools, which rely on tumor size, lymph node involvement, and grade, cast a wide net. Many women flagged as high-risk end up overtreated.
The OPTIMA trial was designed to answer exactly that question using the PAM50-based Prosigna assay, a molecular test that reads gene activity patterns in tumor tissue to estimate recurrence risk. If the ASCO 2026 data hold up in peer review, oncologists treating estrogen-receptor-positive cases will have strong evidence to withhold chemotherapy for a large share of patients who would have received it under current guidelines. The practical effect for patients is straightforward: fewer infusions, fewer side effects, and a faster return to normal life, with no apparent cost in cancer control.
The hypothesis worth tracking is whether clinical practice actually shifts. If hospitals and cancer networks adopt Prosigna-guided decision-making at scale, chemotherapy administration rates for high-risk ER-positive cases should drop measurably within the next 18 months. That change would show up in treatment registries maintained by the NIHR and in population-level databases. Any gap between the trial evidence and real-world prescribing patterns will signal how quickly the oncology community absorbs new data, and where institutional inertia slows the process.
OPTIMA trial design and Prosigna’s performance against rival assays
The OPTIMA program did not begin with the 2026 results. Its preliminary phase, published in the Journal of the National Cancer Institute, tested multiple genomic assays on the same patient population to see whether they agreed on risk classification. The peer-reviewed analysis found that different genomic tools stratified patients differently, with notable variation in how many women each test placed into low-risk versus high-risk categories. Prosigna consistently identified a large group of patients unlikely to benefit from chemotherapy, a finding that informed the design of the full-scale trial.
The main OPTIMA trial enrolled patients whose tumors were estrogen-receptor-positive and clinically high-risk, the exact population where chemotherapy decisions are most contested. Patients received Prosigna testing, and those whose molecular scores indicated low recurrence risk were assigned to endocrine therapy alone, skipping chemotherapy entirely. The trial’s structure, randomizing patients based on genomic rather than purely clinical risk, gave it the power to test whether molecular profiling could safely replace conventional risk assessment for treatment decisions.
Pre-meeting materials from Veracyte, the company behind Prosigna, stated that the results provide new evidence supporting Prosigna-guided chemotherapy decisions in breast cancer. The trial was run independently through the UCL and UCLH system with NIHR funding, which separates its governance from the commercial interests of the test manufacturer. That independence matters for how guideline committees and national health systems will weigh the findings.
UCL described the results as showing that a gene test can safely spare many breast cancer patients from chemotherapy, a framing that reflects the scale of the potential change. The trial’s chief investigator is based at UCL and UCLH, and the study drew on a network of UK clinical sites. Because the NIHR funded the work, the results carry particular weight for NHS treatment policy, though their implications extend to any health system that treats ER-positive breast cancer with chemotherapy as a default for clinically high-risk patients.
Gaps in the evidence and what to watch next
The full ASCO 2026 presentation dataset, including exact recurrence rates, survival endpoints, and subgroup analyses, has not yet appeared in a peer-reviewed journal. The pre-meeting disclosures from Veracyte and UCL describe the topline message but do not provide the granular numbers that clinicians will want to see before changing entrenched practice patterns. That missing detail includes how Prosigna performed across age groups, tumor grades, and varying degrees of lymph node involvement, as well as any signals in small but important subpopulations.
Another open question is how Prosigna compares in head-to-head fashion with other widely used genomic assays. The earlier OPTIMA preliminary work showed that different tests can disagree on which patients fall into low- or high-risk categories. Until the new data are fully published, oncologists will not be able to see whether Prosigna’s chemotherapy-sparing strategy would have matched or diverged from decisions guided by alternative assays. Those comparisons matter for hospitals that already invested in other platforms and must weigh whether switching tests would meaningfully change outcomes or just reshuffle risk labels.
Health systems will also scrutinize follow-up duration. Sparing chemotherapy is only safe if low-risk patients remain free of distant recurrence over many years, not just in the short term. The ASCO presentation is expected to include medium-term outcomes, but longer surveillance will be needed to confirm that no late-emerging risk has been missed. Guideline panels typically look for stable benefit and non-inferiority over a substantial follow-up window before endorsing large-scale de-escalation of therapy.
Cost and access are additional variables that could shape real-world uptake. Genomic assays add upfront expense and require laboratory infrastructure, but they may reduce overall costs if they prevent unnecessary chemotherapy, hospitalizations for side effects, and long-term toxicity management. Payers and national health services will want formal cost-effectiveness analyses, drawing on modeling methods and survival data commonly catalogued through resources such as the National Library of biomedical research. Those analyses will help determine whether Prosigna testing becomes standard of care or remains concentrated in large academic centers.
Equity concerns will surface quickly once Prosigna-guided treatment begins to spread. If access to genomic testing is uneven, some patients may continue to receive default chemotherapy while others benefit from more tailored decisions. Policymakers and professional societies will need to address how to extend testing capacity beyond major urban cancer centers, including training for pathology labs and clear reimbursement rules. Without that groundwork, the trial’s promise of sparing thousands of women from unnecessary chemotherapy could be realized only for a subset of patients.
For now, the OPTIMA results signal a turning point rather than a completed transition. The evidence that many clinically high-risk, estrogen-receptor-positive patients can safely forgo chemotherapy strengthens the case for genomic risk profiling as a routine part of care. The next phase will unfold in guideline meetings, reimbursement negotiations, and multidisciplinary tumor boards where oncologists, surgeons, and pathologists weigh how quickly to move. Tracking chemotherapy rates, test utilization, and long-term outcomes over the coming years will reveal whether Prosigna’s promise in the trial setting translates into durable, system-wide change in how breast cancer is treated.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
